WO1999027897A1 - Site-specific preparation of polyethylene glycol-grf conjugates - Google Patents
Site-specific preparation of polyethylene glycol-grf conjugates Download PDFInfo
- Publication number
- WO1999027897A1 WO1999027897A1 PCT/EP1998/007748 EP9807748W WO9927897A1 WO 1999027897 A1 WO1999027897 A1 WO 1999027897A1 EP 9807748 W EP9807748 W EP 9807748W WO 9927897 A1 WO9927897 A1 WO 9927897A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hgrf
- peg
- lys
- conjugates
- peptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (24)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UA2000063885A UA73716C2 (en) | 1997-12-03 | 1998-01-12 | Site-specific preparation of grf conjugated with polyethylene glycol |
BR9815159-2A BR9815159A (en) | 1997-12-03 | 1998-12-01 | Preparation of site-specific polyethylene glycol-grf conjugates |
IL13655198A IL136551A0 (en) | 1997-12-03 | 1998-12-01 | Preparation of peg-grf conjugates |
AU15633/99A AU755285B2 (en) | 1997-12-03 | 1998-12-01 | Site-specific preparation of polyethylene glycol-GRF conjugates |
NZ504570A NZ504570A (en) | 1997-12-03 | 1998-12-01 | Site-specific preparation of hGRF-PEG with PEG units covalently bound to Lys12, Lys21 or amino terminal |
DE69813291T DE69813291T2 (en) | 1997-12-03 | 1998-12-01 | MANUFACTURING SITE-SPECIFIC POLYETHYLENE GLYCOL-GRF CONJUGATES |
PL341139A PL192082B1 (en) | 1997-12-03 | 1998-12-01 | Method for oriented production of hGRF-PEG conjugate, hGRF-PEG conjugate and its application, [Lys (alloc)¹²ˑ²¹] - hGRF compound and [N α-isopropyl- Tyr ¹, Lys (Alloc)¹²]- hGRF compound as well as pharmaceutical compound as such |
EA200000601A EA004269B1 (en) | 1997-12-03 | 1998-12-01 | Method for site-specific preparation of conjugates of human growth hormone releasing factor and polyethylene glycol, conjugates, prepared according to that method, use in production of a medicament thereof |
SK824-2000A SK8242000A3 (en) | 1997-12-03 | 1998-12-01 | Site-specific preparation of polyethylene glycol-grf conjugates |
KR1020007005736A KR100561768B1 (en) | 1997-12-03 | 1998-12-01 | Site-specific preparation of polyethylene glycol-grf conjugates |
EEP200000319A EE200000319A (en) | 1997-12-03 | 1998-12-01 | Site-Specific Method for the Preparation of hGRF-PEG Conjugates, hGRF-PEG Conjugates, Intermediates, Use, and Pharmaceutical Composition |
JP2000522885A JP2001524505A (en) | 1997-12-03 | 1998-12-01 | Method for site-specific preparation of polyethylene glycol-GRF conjugate |
SI9830400T SI1037587T1 (en) | 1997-12-03 | 1998-12-01 | Site-specific preparation of polyethylene glycol-grf conjugates |
EP98959898A EP1037587B1 (en) | 1997-12-03 | 1998-12-01 | Site-specific preparation of polyethylene glycol-grf conjugates |
DK98959898T DK1037587T3 (en) | 1997-12-03 | 1998-12-01 | Site-specific preparation of polyethylene glycol-GRF conjugates |
HU0100507A HUP0100507A3 (en) | 1997-12-03 | 1998-12-01 | Polyethylene glycol-grf conjugates, site-specific preparation thereof, pharmaceutical compositions comprising thereof and their use |
AT98959898T ATE236607T1 (en) | 1997-12-03 | 1998-12-01 | PREPARATION OF SITE-SPECIFIC POLYETHYLENE GLYCOL-GRF CONJUGATES |
CA002312004A CA2312004C (en) | 1997-12-03 | 1998-12-01 | Site-specific preparation of polyethylene glycol-grf conjugates |
NO20002664A NO327238B1 (en) | 1997-12-03 | 2000-05-24 | Method for the site-specific preparation of hGRF-PEG conjugates, GRF-PEG conjugates, use thereof for the preparation of a medicament and a pharmaceutical composition comprising the same. |
IL136551A IL136551A (en) | 1997-12-03 | 2000-06-04 | Preparation of peg-grf conjugates |
US09/587,460 US6528485B1 (en) | 1997-12-03 | 2000-06-05 | Site-specific preparation of polyethylene glycol-grf conjugates |
HK01104960A HK1034203A1 (en) | 1997-12-03 | 2001-07-16 | Site-specific preparation of polyethylene glycol-grf conjugates |
US10/299,790 US6869932B2 (en) | 1997-12-03 | 2002-11-20 | Site-specific preparation of polyethlene glycol-GRF conjugates |
US11/011,617 US7317002B2 (en) | 1997-12-03 | 2004-12-15 | Site-specific preparation of polyethylene glycol-GRF conjugates |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97121264A EP0922446A1 (en) | 1997-12-03 | 1997-12-03 | Solution-phase site-specific preparation of GRF-PEG conjugates |
EP97121264.2 | 1997-12-03 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/587,460 Continuation US6528485B1 (en) | 1997-12-03 | 2000-06-05 | Site-specific preparation of polyethylene glycol-grf conjugates |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999027897A1 true WO1999027897A1 (en) | 1999-06-10 |
WO1999027897A9 WO1999027897A9 (en) | 1999-09-30 |
Family
ID=8227732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/007748 WO1999027897A1 (en) | 1997-12-03 | 1998-12-01 | Site-specific preparation of polyethylene glycol-grf conjugates |
Country Status (30)
Country | Link |
---|---|
US (3) | US6528485B1 (en) |
EP (2) | EP0922446A1 (en) |
JP (2) | JP2001524505A (en) |
KR (1) | KR100561768B1 (en) |
CN (1) | CN1149967C (en) |
AR (1) | AR017780A1 (en) |
AT (1) | ATE236607T1 (en) |
AU (1) | AU755285B2 (en) |
BG (1) | BG64815B1 (en) |
BR (1) | BR9815159A (en) |
CA (1) | CA2312004C (en) |
DE (1) | DE69813291T2 (en) |
DK (1) | DK1037587T3 (en) |
EA (1) | EA004269B1 (en) |
EE (1) | EE200000319A (en) |
ES (1) | ES2194376T3 (en) |
HK (1) | HK1034203A1 (en) |
HU (1) | HUP0100507A3 (en) |
IL (2) | IL136551A0 (en) |
NO (1) | NO327238B1 (en) |
NZ (1) | NZ504570A (en) |
PL (1) | PL192082B1 (en) |
PT (1) | PT1037587E (en) |
SI (1) | SI1037587T1 (en) |
SK (1) | SK8242000A3 (en) |
TR (1) | TR200001615T2 (en) |
TW (1) | TWI254641B (en) |
UA (1) | UA73716C2 (en) |
WO (1) | WO1999027897A1 (en) |
ZA (1) | ZA9811068B (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002028437A1 (en) * | 2000-10-05 | 2002-04-11 | Ares Trading S.A. | Regioselective liquid phase pegylation |
WO2004065412A1 (en) * | 2003-01-18 | 2004-08-05 | Pegsphere Co., Ltd. | Peptides having protected amines of untargeted sites, methods for production thereof and of specifically conjugated peg peptides using the same |
WO2009026393A2 (en) * | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
US7632492B2 (en) | 2006-05-02 | 2009-12-15 | Allozyne, Inc. | Modified human interferon-β polypeptides |
WO2017181277A1 (en) * | 2016-04-19 | 2017-10-26 | Griffon Pharmaceuticals Inc. | Pegylated bioactive peptides and uses thereof |
US10407482B2 (en) | 2006-05-02 | 2019-09-10 | Allozyne, Inc. | Amino acid substituted molecules |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010055581A1 (en) | 1994-03-18 | 2001-12-27 | Lawrence Tamarkin | Composition and method for delivery of biologically-active factors |
US6407218B1 (en) * | 1997-11-10 | 2002-06-18 | Cytimmune Sciences, Inc. | Method and compositions for enhancing immune response and for the production of in vitro mabs |
US7229841B2 (en) * | 2001-04-30 | 2007-06-12 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
EP1234583A1 (en) | 2001-02-23 | 2002-08-28 | F. Hoffmann-La Roche Ag | PEG-conjugates of HGF-NK4 |
US20030171285A1 (en) * | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
DE60315949T2 (en) | 2002-01-16 | 2008-06-12 | Biocompatibles Uk Ltd., Farnham | polymer conjugates |
US7998705B2 (en) * | 2002-08-06 | 2011-08-16 | FUJIFILM Diosynth Biotechnologies U.S.A., Inc | Increased dynamic binding capacity in ion exchange chromatography by addition of polyethylene glycol |
CA2496687A1 (en) * | 2002-09-18 | 2004-04-01 | Centre Hospitalier De L'universite De Montreal (Chum) | Ghrh analogues |
GB0301014D0 (en) * | 2003-01-16 | 2003-02-19 | Biocompatibles Ltd | Conjugation reactions |
WO2005010163A2 (en) * | 2003-07-15 | 2005-02-03 | Barros Research Institute | Compositions and methods for immunotherapy of human immunotherapy of human immunodeficiency virus (hiv) |
JP2008500005A (en) * | 2003-07-15 | 2008-01-10 | バロス リサーチ インスティテュート | Compositions and methods for immunotherapy of cancer and infectious diseases |
JP2008504216A (en) * | 2003-12-02 | 2008-02-14 | サイトイミューン サイエンシズ インコーポレイテッド | Methods and compositions for the production of monoclonal antibodies |
US20050175584A1 (en) * | 2004-01-28 | 2005-08-11 | Paciotti Giulio F. | Functionalized colloidal metal compositions and methods |
CN100355784C (en) * | 2004-02-12 | 2007-12-19 | 江苏恒瑞医药股份有限公司 | Method for preparing polyethylene glycol-modified alpha-interferon 1b |
US20050261475A1 (en) * | 2004-02-13 | 2005-11-24 | Harvard Medical School | Solid-phase capture-release-tag methods for phosphoproteomic analyses |
US6986264B1 (en) * | 2004-07-15 | 2006-01-17 | Carrier Corporation | Economized dehumidification system |
KR20180110192A (en) | 2004-11-12 | 2018-10-08 | 바이엘 헬스케어 엘엘씨 | Site-directed modification of fviii |
JP2009503191A (en) | 2005-07-26 | 2009-01-29 | ローディア インコーポレイティド | Polymers with pendant poly (alkyleneoxy) substituents and their use in personal care applications |
US20070238656A1 (en) * | 2006-04-10 | 2007-10-11 | Eastman Kodak Company | Functionalized poly(ethylene glycol) |
US8765924B2 (en) * | 2006-08-04 | 2014-07-01 | Prolong Pharmaceuticals, Inc. | Modified erythropoietin |
US20080083154A1 (en) * | 2006-10-05 | 2008-04-10 | Timothy M Gregory | Bait retention fish hook |
US20110014118A1 (en) * | 2007-09-21 | 2011-01-20 | Lawrence Tamarkin | Nanotherapeutic colloidal metal compositions and methods |
KR20100123674A (en) * | 2007-09-21 | 2010-11-24 | 싸이티뮨 사이언스, 인크. | Nanotherapeutic colloidal metal compositions and methods |
CA2706700A1 (en) | 2007-11-08 | 2009-05-14 | Cytimmune Sciences, Inc. | Compositions and methods for generating antibodies |
ES2723098T3 (en) * | 2008-11-04 | 2019-08-21 | Janssen Pharmaceutica Nv | CRHR2 peptide agonists and uses thereof |
PL2408800T3 (en) * | 2009-03-20 | 2016-11-30 | Method for preparing a site-specific conjugate of a physiologically active polypeptide | |
US20100267635A1 (en) * | 2009-04-20 | 2010-10-21 | Theratechonolgies Inc. | Use of protease inhibitors and grf molecules in combination therapy |
US20100267636A1 (en) * | 2009-04-20 | 2010-10-21 | Theratechnologies Inc. | Use of cytochrome p450-metabolized drugs and grf molecules in combination therapy |
CA2766634A1 (en) | 2009-06-22 | 2011-01-13 | Burnham Institute For Medical Research | Methods and compositions using peptides and proteins with c-terminal elements |
BR112012010661A2 (en) | 2009-11-04 | 2016-11-22 | Janssen Pharmaceutica Nv | method for treating heart failure with stressecopine-like peptides |
WO2012118778A1 (en) | 2011-02-28 | 2012-09-07 | Sanford-Burnham Medical Research Institute | Truncated car peptides and methods and compositions using truncated car peptides |
WO2012142706A1 (en) | 2011-04-21 | 2012-10-26 | Theratechnologies Inc. | Growth hormone releasing factor (grf) analogs and uses thereof |
AU2012262488A1 (en) | 2011-05-31 | 2014-01-16 | Airware, Inc. | Re-calibration of AB NDIR gas sensors |
US10179801B2 (en) | 2011-08-26 | 2019-01-15 | Sanford-Burnham Medical Research Institute | Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides |
WO2013190520A2 (en) | 2012-06-22 | 2013-12-27 | The General Hospital Corporation | Gh-releasing agents in the treatment of vascular stenosis and associated conditions |
US10064940B2 (en) | 2013-12-11 | 2018-09-04 | Siva Therapeutics Inc. | Multifunctional radiation delivery apparatus and method |
CA2986927C (en) | 2015-05-28 | 2023-12-19 | Institut National De La Recherche Scientifique | Inhibitors of prototypic galectin dimerization and uses thereof |
CN110317826B (en) * | 2019-05-22 | 2020-11-10 | 中国农业大学 | Application of substance for regulating content or activity of PvGRF9 in regulation of plant stem growth and development |
WO2021133407A1 (en) | 2019-12-27 | 2021-07-01 | Compagnie Generale Des Etablissements Michelin | Rubber mix with high specific surface area and high structure acetylene carbon black |
US11623949B2 (en) | 2021-01-28 | 2023-04-11 | Talem Therapeutics Llc | Anti-spike glycoprotein antibodies and the therapeutic use thereof |
WO2024081918A1 (en) | 2022-10-14 | 2024-04-18 | Talem Therapeutics Llc | Anti-trkb/cd3 antibodies and uses thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0400472A2 (en) * | 1989-05-27 | 1990-12-05 | Sumitomo Pharmaceuticals Company, Limited | Process for preparing polyethylene glycol derivatives and modified protein. |
EP0473084A2 (en) * | 1990-08-28 | 1992-03-04 | Sumitomo Pharmaceuticals Company, Limited | Polyethylene glycol derivatives, their modified peptides, methods for producing them and use of the modified peptides |
EP0518295A2 (en) * | 1991-06-14 | 1992-12-16 | Millipore Corporation | Allyl side chain protection in peptide synthesis |
WO1996021469A1 (en) * | 1995-01-10 | 1996-07-18 | Shearwater Polymers, Inc. | Multi-armed, monofunctional, and hydrolytically stable derivatives of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
WO1997017367A1 (en) * | 1995-11-03 | 1997-05-15 | Theratechnologies Inc. | Method of grf peptides synthesis |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4563352A (en) * | 1982-10-04 | 1986-01-07 | The Salk Institute For Biological Studies | Human pancreatic GRF |
ZA914983B (en) * | 1990-06-29 | 1992-03-25 | Hoffmann La Roche | His-grf-analogs |
WO1992018531A1 (en) * | 1991-04-09 | 1992-10-29 | F. Hoffmann-La Roche Ag | Growth hormone releasing factor analogs |
FR2687681B1 (en) * | 1992-02-20 | 1995-10-13 | Transgene Sa | POLYETHYLENEGLYCOL-HIRUDINE CONJUGATES, THEIR PREPARATION PROCESS AND THEIR USE FOR THE TREATMENT OF THROMBOSES. |
-
1997
- 1997-12-03 EP EP97121264A patent/EP0922446A1/en not_active Withdrawn
-
1998
- 1998-01-12 UA UA2000063885A patent/UA73716C2/en unknown
- 1998-12-01 HU HU0100507A patent/HUP0100507A3/en unknown
- 1998-12-01 KR KR1020007005736A patent/KR100561768B1/en not_active IP Right Cessation
- 1998-12-01 SK SK824-2000A patent/SK8242000A3/en unknown
- 1998-12-01 PT PT98959898T patent/PT1037587E/en unknown
- 1998-12-01 AU AU15633/99A patent/AU755285B2/en not_active Expired
- 1998-12-01 CA CA002312004A patent/CA2312004C/en not_active Expired - Lifetime
- 1998-12-01 CN CNB988117592A patent/CN1149967C/en not_active Expired - Fee Related
- 1998-12-01 BR BR9815159-2A patent/BR9815159A/en not_active Application Discontinuation
- 1998-12-01 ES ES98959898T patent/ES2194376T3/en not_active Expired - Lifetime
- 1998-12-01 DK DK98959898T patent/DK1037587T3/en active
- 1998-12-01 SI SI9830400T patent/SI1037587T1/en unknown
- 1998-12-01 EA EA200000601A patent/EA004269B1/en not_active IP Right Cessation
- 1998-12-01 WO PCT/EP1998/007748 patent/WO1999027897A1/en active IP Right Grant
- 1998-12-01 EE EEP200000319A patent/EE200000319A/en unknown
- 1998-12-01 EP EP98959898A patent/EP1037587B1/en not_active Expired - Lifetime
- 1998-12-01 DE DE69813291T patent/DE69813291T2/en not_active Expired - Lifetime
- 1998-12-01 PL PL341139A patent/PL192082B1/en not_active IP Right Cessation
- 1998-12-01 IL IL13655198A patent/IL136551A0/en unknown
- 1998-12-01 AT AT98959898T patent/ATE236607T1/en active
- 1998-12-01 NZ NZ504570A patent/NZ504570A/en unknown
- 1998-12-01 JP JP2000522885A patent/JP2001524505A/en active Pending
- 1998-12-01 TR TR2000/01615T patent/TR200001615T2/en unknown
- 1998-12-02 AR ARP980106098A patent/AR017780A1/en active IP Right Grant
- 1998-12-03 ZA ZA9811068A patent/ZA9811068B/en unknown
-
1999
- 1999-01-26 TW TW088101139A patent/TWI254641B/en not_active IP Right Cessation
-
2000
- 2000-05-24 NO NO20002664A patent/NO327238B1/en not_active IP Right Cessation
- 2000-05-29 BG BG10448A patent/BG64815B1/en unknown
- 2000-06-04 IL IL136551A patent/IL136551A/en not_active IP Right Cessation
- 2000-06-05 US US09/587,460 patent/US6528485B1/en not_active Expired - Lifetime
-
2001
- 2001-07-16 HK HK01104960A patent/HK1034203A1/en not_active IP Right Cessation
-
2002
- 2002-11-20 US US10/299,790 patent/US6869932B2/en not_active Expired - Lifetime
-
2004
- 2004-12-15 US US11/011,617 patent/US7317002B2/en not_active Expired - Fee Related
-
2009
- 2009-10-30 JP JP2009251100A patent/JP5431874B2/en not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0400472A2 (en) * | 1989-05-27 | 1990-12-05 | Sumitomo Pharmaceuticals Company, Limited | Process for preparing polyethylene glycol derivatives and modified protein. |
EP0473084A2 (en) * | 1990-08-28 | 1992-03-04 | Sumitomo Pharmaceuticals Company, Limited | Polyethylene glycol derivatives, their modified peptides, methods for producing them and use of the modified peptides |
EP0518295A2 (en) * | 1991-06-14 | 1992-12-16 | Millipore Corporation | Allyl side chain protection in peptide synthesis |
WO1996021469A1 (en) * | 1995-01-10 | 1996-07-18 | Shearwater Polymers, Inc. | Multi-armed, monofunctional, and hydrolytically stable derivatives of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
WO1997017367A1 (en) * | 1995-11-03 | 1997-05-15 | Theratechnologies Inc. | Method of grf peptides synthesis |
Non-Patent Citations (7)
Title |
---|
CAMPBELL RM ET AL: "Pegylated peptides. V. Carboxy-terminal PEGylated analogs of growth hormone-releasing factor (GRF) display enhanced duration of biological activity in vivo.", J PEPT RES, JUN 1997, 49 (6) P527-37, DENMARK, XP000657594 * |
FELIX AM ET AL: "Pegylated peptides. IV. Enhanced biological activity of site-directed pegylated GRF analogs.", INT J PEPT PROTEIN RES, SEP-OCT 1995, 46 (3-4) P253-64, DENMARK, XP002064559 * |
FISCHER D ET AL: "PEG-PROTEIN CONSTRUCTS FOR CLINICAL USE", PERSPECTIVE PROTEIN ENG. COMPLEMENTARY TECHNOLOGY COLLECT PAPERS INTERNATIONAL SYMPOSIUM, 1995, pages 223 - 226, XP002060507 * |
FRANCIS G E ET AL: "POLYETHYLENE GLYCOL MODIFICATION: RELEVANCE OF IMPROVED METHODOLOGY TO TUMOUR TARGETING", JOURNAL OF DRUG TARGETING, vol. 3, 1996, pages 321 - 340, XP002058312 * |
GAERTNER H F ET AL: "SITE-SPECIFIC ATTACHMENT OF FUNCTIONALIZED POLY(ETHYLENE GLYCOL) TOTHE AMINO TERMINUS OF PROTEINS", BIOCONJUGATE CHEMISTRY, vol. 7, no. 1, 1996, pages 38 - 44, XP000646874 * |
ZALIPSKY S: "CHEMISTRY OF POLYETHYLENE GLYCOL CONJUGATES WITH BIOLOGICALLY ACTIVE MOLECULES", ADVANCED DRUG DELIVERY REVIEWS, vol. 16, no. 2/03, 1995, pages 157 - 182, XP002037428 * |
ZHANG C. ET AL: "Radioimmunoassay of growth hormone-releasing hormone (GHRH) with a polyclonal antibody against synthetic GHRH(1-29)-Gly4-Cys-NH2: Method and clinical studies", CLIN. CHIM. ACTA, 1991, 202/3 (243-254), NETHERLANDS, XP002064562 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002028437A1 (en) * | 2000-10-05 | 2002-04-11 | Ares Trading S.A. | Regioselective liquid phase pegylation |
AU2001295589B2 (en) * | 2000-10-05 | 2005-10-13 | Ares Trading S.A. | Regioselective liquid phase pegylation |
US7256258B2 (en) | 2000-10-05 | 2007-08-14 | Ares Trading S.A. | Regioselective liquid phase pegylation |
WO2004065412A1 (en) * | 2003-01-18 | 2004-08-05 | Pegsphere Co., Ltd. | Peptides having protected amines of untargeted sites, methods for production thereof and of specifically conjugated peg peptides using the same |
CN100357313C (en) * | 2003-01-18 | 2007-12-26 | 派格斯菲尔有限公司 | Peptides having protected amines of untargeted sites, methods for production thereof and of specifically conjugated PEG peptides using the same |
US7829659B2 (en) | 2006-05-02 | 2010-11-09 | Allozyne, Inc. | Methods of modifying polypeptides comprising non-natural amino acids |
US7632492B2 (en) | 2006-05-02 | 2009-12-15 | Allozyne, Inc. | Modified human interferon-β polypeptides |
US10407482B2 (en) | 2006-05-02 | 2019-09-10 | Allozyne, Inc. | Amino acid substituted molecules |
WO2009026393A3 (en) * | 2007-08-20 | 2009-06-25 | Allozyne Inc | Amino acid substituted molecules |
WO2009026393A2 (en) * | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
EP3445778A4 (en) * | 2016-04-19 | 2019-05-01 | Griffon Pharmaceuticals Inc. | Pegylated bioactive peptides and uses thereof |
KR20180135016A (en) * | 2016-04-19 | 2018-12-19 | 그리폰 파마수티컬스 인크. | Pegylated live peptides and uses thereof |
US9988428B2 (en) | 2016-04-19 | 2018-06-05 | Griffon Pharmaceuticals Inc. | Pegylated bioactive peptides and uses thereof |
WO2017181277A1 (en) * | 2016-04-19 | 2017-10-26 | Griffon Pharmaceuticals Inc. | Pegylated bioactive peptides and uses thereof |
AU2017254754B2 (en) * | 2016-04-19 | 2021-02-04 | Griffon Pharmaceuticals International Sa | PEGylated bioactive peptides and uses thereof |
US10918730B2 (en) | 2016-04-19 | 2021-02-16 | Griffon Pharmaceuticals International Sa | Pegylated bioactive peptides and uses thereof |
RU2748576C2 (en) * | 2016-04-19 | 2021-05-27 | Гриффон Фармасьютикалз Интернешнл Са. | Pegilated biologically active peptides and their application |
KR102520348B1 (en) | 2016-04-19 | 2023-04-10 | 그리폰 파마수티컬스 인터내셔널 에스에이 | PEGylated Bioactive Peptides and Uses Thereof |
IL262356B2 (en) * | 2016-04-19 | 2023-06-01 | Griffon Pharmaceuticals Inc | Pegylated bioactive peptides and uses thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1037587B1 (en) | Site-specific preparation of polyethylene glycol-grf conjugates | |
US7256258B2 (en) | Regioselective liquid phase pegylation | |
CA2737040C (en) | Polymer conjugates of therapeutic peptides | |
US20080085860A1 (en) | Selective Vpac2 Receptor Peptide Agonists | |
AU2001295589A1 (en) | Regioselective liquid phase pegylation | |
US7897573B2 (en) | Selective VPAC2 receptor peptide agonists | |
US20090118167A1 (en) | Selective Vpac2 Receptor Peptide Agonists | |
MX2007000568A (en) | Conjugates of a gm-csf moiety and a polymer. | |
CN113710692A (en) | Long-acting GLP-2 analogs | |
US20020183257A1 (en) | PEG-LHRH analog conjugates | |
MXPA00005138A (en) | Site-specific preparation of polyethylene glycol-grf conjugates | |
CZ20002055A3 (en) | Selective preparation process of specific conjugates polyethylene glycol - GRF | |
US20210187077A1 (en) | GLP-1 Agonist Conjugates for Sustained Glycemic Control |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 136551 Country of ref document: IL Ref document number: 98811759.2 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 3/14-5/14, DRAWINGS, REPLACED BY NEW PAGES 3/14-5/14; AFTER RECTIFICATION OF OBVIOUS ERRORS AS AUTHORIZED BY THE INTERNATIONAL SEARCHING AUTHORITY |
|
WWE | Wipo information: entry into national phase |
Ref document number: 504570 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15633/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/005138 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007005736 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2312004 Country of ref document: CA Ref document number: 2312004 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 8242000 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2000-2055 Country of ref document: CZ Ref document number: 2000/01615 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09587460 Country of ref document: US Ref document number: 1998959898 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200000601 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 1998959898 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV2000-2055 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007005736 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 15633/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998959898 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020007005736 Country of ref document: KR |